ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026
An Immunomodulating Peptide With Potential to Counteract Endometriosis.
Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is underpinned by dysfunctional immune responses resulting in failure to clear ectopic endometrial lesions from the peritoneal cavity. The pelvic milieu comprising immature dendritic cells, dysfunctional cytotoxic lymphocytes, and an imbalance in production of interleukin-12 isoforms including Type I/II interferons (IFNs) is thought to play a major role in this process. The recent discovery of an immunomodulating lipidic peptide, designated IK14004, that activates natural killer (NK) and CD8+ T cells, skews IL-12 signalling towards the IL-12p70 isoform and uncouples production of Type I from Type II IFNs may enable earlier diagnosis of endometriosis and could also have therapeutic benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.